Abstract
Radiation therapy (RT) is a standard treatment for rectal cancer (RC), but its long-term effects on surrounding organs remain a concern. This large-scale population-based study investigates the risk and prognosis of secondary bladder cancer (SBC) following RT for rectal cancer. The analysis reveals that radiation is associated with a significantly increased risk of developing SBC, particularly in younger patients and those with longer survival times. Given these findings, specialized long-term surveillance for bladder cancer is recommended for RC survivors who received radiation.
Introduction
Radiation therapy is a cornerstone of treatment for locally advanced rectal cancer, significantly improving local control and patient survival. However, ionizing radiation can induce DNA damage in healthy tissues adjacent to the target area. The bladder, due to its proximity to the rectum, is frequently exposed to scatter radiation, potentially leading to secondary primary cancers (SPCs) years or even decades later.
Previous research into the link between rectal cancer radiation and secondary bladder cancer has yielded inconsistent results, often limited by small sample sizes or insufficient follow-up. Furthermore, the prognosis of these secondary cancers—whether they behave more aggressively than primary bladder cancers—remained poorly understood. This study utilizes a massive population-based dataset to quantify both the risk and the long-term survival outcomes of SBC in this patient population.
Methods
The researchers conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER-9) database, analyzing data from patients diagnosed between 1973 and 2015. To ensure a rigorous analysis, the study employed several sophisticated statistical techniques:
- Fine and Gray’s Competing Risk Regression: This model was used to estimate the cumulative incidence of SBC while accounting for the competing risk of death from the primary rectal cancer or other causes.
- Standardized Incidence Ratio (SIR): This metric compared the incidence of bladder cancer in the RC cohort directly against the general US population.
- Propensity Score Matching (PSM): To compare survival outcomes fairly, researchers matched patients with similar clinical characteristics (age, race, tumor stage) to isolate the specific impact of prior radiation.
Results
Increased Risk of Secondary Bladder Cancer
Of the 74,646 rectal cancer patients identified in the study, those who received radiation therapy had a significantly higher cumulative incidence of secondary bladder cancer compared to those treated with surgery alone. Specifically, the incidence was 1.85% in the RT group versus 1.24% in the non-RT group (P=0.015).
Multivariable analysis confirmed that undergoing RT was associated with a 44.3% higher risk of developing SBC (HR 1.443, 95% CI 1.209-1.720, P<0.001). Furthermore, RC survivors who received RT were 35% more likely to develop bladder cancer than the general US population (SIR 1.35).
Subgroup Analysis and Hazard Ratios
The increased risk was observed across various patient subgroups. Notably, younger patients (ages 20–49) at the time of RC diagnosis faced the highest relative risk compared to the general population, likely due to the longer "biological window" for radiation-induced mutations to manifest.
Prognosis and Survival
While RT increases the risk of developing SBC, the study found that once SBC occurs, the survival outcomes (Overall Survival and Cancer-Specific Survival) are similar regardless of whether the patient had prior radiation. However, all patients with secondary bladder cancer had significantly poorer outcomes compared to patients with primary bladder cancer (OPBC). For instance, the 10-year overall survival for SBC patients with prior RT was only 24.8%, compared to 37.9% for matched primary bladder cancer patients.
Discussion and Limitations
The study highlights a clear "latency effect," where the risk of SBC increases over time, reaching its peak more than 20 years after the initial radiation treatment. This underscores the need for lifelong monitoring.
However, there are limitations to the SEER database analysis. The data lacks granular details on radiation doses and fractionation schedules, as well as lifestyle factors like smoking history, which is a major risk factor for bladder cancer. Additionally, the study spans 40 years, during which radiation techniques have evolved from 2D/3D methods to more precise Intensity-Modulated Radiation Therapy (IMRT). Future research is needed to determine if modern, targeted techniques mitigate these long-term risks.
Conclusion
Radiation therapy significantly increases the long-term risk of secondary bladder cancer in rectal cancer survivors. While the prognosis of SBC is not worsened by the prior radiation itself, it remains poorer than that of primary bladder cancer. Clinicians should prioritize long-term bladder surveillance for RC survivors, particularly those treated at a younger age, to ensure early detection and management of secondary malignancies.
Summary updated